Page 20 - Read Online

17. Chin L, Andersen JN, Futreal PA. Cancer genomics: From Golub TR, Sugarbaker DJ, Meyerson M. Classifi cation of
discovery science to personalized medicine. Nat Med human lung carcinomas by mRNA expression profi ling reveals
2011;17:297-303. distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A
18. Berman DM, Bosenberg MW, Orwant RL, Thurberg BL, 2001;98:13790-5.
Draetta GF, Fletcher CD, Loda M. Investigative pathology: 30. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS,
Leading the post-genomic revolution. Lab Invest Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
2012;92:4-8. Fluge O, Pergamenschikov A, Williams C, Zhu SX,
19. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D.
Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Molecular portraits of human breast tumours. Nature
Danenberg PV, Kuramochi H, Tanaka K, Singh S, 2000;406:747-52.
Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, 31. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D,
Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF,
Maitra A, Hidalgo M. An in vivo platform for translational Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E,
drug development in pancreatic cancer. Clin Cancer Res Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised
2006;12:4652-61. risk predictor of breast cancer based on intrinsic subtypes.
20. Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goéré D, J Clin Oncol 2009;27:1160-7.
Mariani P, Landron S, Bigot L, Nemati F, Dartigues P, 32. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA,
Weiswald LB, Lantuas D, Morgand L, Pham E, Gonin P, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ,
Dangles-Marie V, Job B, Dessen P, Bruno A, Pierre A, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L,
De The H, Soliman H, Nunes M, Lardier G, Calvet L, Demers B, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET,
Prevost G, Vrignaud P, Roman-Roman S, Duchamp O, Friend SH, Bernards R. A gene-expression signature as a predictor
Berthet C. Characterization of a large panel of patient-derived of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
tumor xenografts representing the clinical heterogeneity of 33. Lehmann BD, Bauer JA, Chen X, Sanders ME,
human colorectal cancer. Clin Cancer Res 2012;18:5314-28. Chakravarthy AB, Shyr Y, Pietenpol JA. Identifi cation of
21. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, human triple-negative breast cancer subtypes and preclinical
Isella C, Cora D, Di Nicolantonio F, Buscarino M, models for selection of targeted therapies. J Clin Invest
Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, 2011;121:2750-67.
Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, 34. Zhou JX, Yang H, Deng Q, Gu X, He P, Lin Y, Zhao M,
Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Jiang J, Chen H, Lin Y, Yin W, Mo L, He J. Oncogenic
Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L. driver mutations in patients with non-small-cell lung cancer at
A molecularly annotated platform of patient-derived various clinical stages. Ann Oncol 2013;24:1319-25.
xenografts (“xenopatients”) identifi es HER2 as an effective 35. Chen Z, Feng J, Saldivar JS, Gu D, Bockholt A, Sommer SS.
therapeutic target in cetuximab-resistant colorectal cancer. EGFR somatic doublets in lung cancer are frequent and
Cancer Discov 2011;1:508-23. generally arise from a pair of driver mutations uncommonly
22. Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, seen as singlet mutations: One-third of doublets occur at fi ve
Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, pairs of amino acids. Oncogene 2008;27:4336-43.
Park JW, Spellman PT, Gray JW, Van’t Veer L, Esserman LJ. 36. Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D,
Xenografts faithfully recapitulate breast cancer-specifi c Kasper LH, Plenker D, Leenders F, Sun R, Zander T,
gene expression patterns of parent primary breast tumors. Menon R, Koker M, Dahmen I, Muller C, Di Cerbo V,
Breast Cancer Res Treat 2012;135:913-22. Schildhaus HU, Altmuller J, Baessmann I, Becker C,
23. Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, de Wilde B, Vandesompele J, Bohm D, Ansen S, Gabler F,
Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, Wilkening I, Heynck S, Heuckmann JM, Lu X, Carter SL,
de Cremoux P, Gestraud P, Vincent-Salomon A, Fontaine JJ, Cibulskis K, Banerji S, Getz G, Park KS, Rauh D, Grutter C,
Roman-Roman S, Delattre O, Decaudin D, Marangoni E. Fischer M, Pasqualucci L, Wright G, Wainer Z, Russell P,
Molecular profi ling of patient-derived breast cancer xenografts. Petersen I, Chen Y, Stoelben E, Ludwig C, Schnabel P,
Breast Cancer Res 2012;14:R11. Hoffmann H, Muley T, Brockmann M, Engel-Riedel W,
24. Siolas D, Hannon GJ. Patient-derived tumor xenografts: Muscarella LA, Fazio VM, Groen H, Timens W, Sietsma H,
Transforming clinical samples into mouse models. Cancer Res Thunnissen E, Smit E, Heideman DA, Snijders PJ,
2013;73:5315-9. Cappuzzo F, Ligorio C, Damiani S, Field J, Solberg S,
Brustugun OT, Lund-Iversen M, Sanger J, Clement JH,
25. Mardis ER. Genome sequencing and cancer. Soltermann A, Moch H, Weder W, Solomon B, Soria JC,
Curr Opin Genet Dev 2012;22:245-50. Validire P, Besse B, Brambilla E, Brambilla C, Lantuejoul S,
26. Baron JA. Screening for cancer with molecular markers: Lorimier P, Schneider PM, Hallek M, Pao W, Meyerson M,
Progress comes with potential problems. Nat Rev Cancer Sage J, Shendure J, Schneider R, Buttner R, Wolf J,
2012;12:368-71. Nurnberg P, Perner S, Heukamp LC, Brindle PK, Haas S,
27. Sleijfer S, Bogaerts J, Siu LL. Designing transformative Thomas RK. Integrative genome analyses identify key
clinical trials in the cancer genome era. J Clin Oncol somatic driver mutations of small-cell lung cancer. Nat Genet
2013;31:1834-41. 2012;44:1104-10.
28. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, 37. Loukopoulos P, Kanetaka K, Takamura M, Shibata T,
Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Sakamoto M, Hirohashi S. Orthotopic transplantation models
Bloomfi eld CD, Lander ES. Molecular classifi cation of cancer: of pancreatic adenocarcinoma derived from cell lines and
Class discovery and class prediction by gene expression primary tumors and displaying varying metastatic activity.
monitoring. Science 1999;286:531-7. Pancreas 2004;29:193-203.
29. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, 38. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS,
Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E,
Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL.

Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 1 ¦ April 15, 2015 ¦ 13